Alina Soare

TL;DR: Fostering IL-9-mediated ILC2 activation may offer a novel therapeutic approach inducing resolution of inflammation rather than suppression of inflammatory responses, as patients with rheumatoid arthritis in remission exhibited high numbers of IL- 9+ ILC 2s in joints and the circulation.

TL;DR: Nintedanib targets core features of SSc in Fra2-transgenic mice and ameliorates histological features of pulmonary arterial hypertension, destructive microangiopathy and pulmonary and dermal fibrosis.

TL;DR: This finding may profoundly change the management of certain forms of immune-mediated disease, such as IgG4-related disease, as subtypes dominated by fibrosis may require different approaches to control disease progression, for example, specific antifibrotic agents rather than broad spectrum anti-inflammatory treatments such as glucocorticoids.

TL;DR: Evaluated DPP‐4 as a potential target for the treatment of fibrosis in patients with systemic sclerosis and identified a dermal fibroblast lineage involved in scarring during wound healing.

TL;DR: In this paper, the authors discuss novel insights into the pathogenesis of fibrotic diseases using systemic sclerosis (SSc) as example for an idiopathic, multisystem disorder.